Skip to content
Catalyst

PapersPMID:27912875

Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.

Phytomedicine2016The record ↗

findings
3
compound
1
endpoints
3
PMID:27912875
  1. Finding, moderate evidencelowersBody mass
  2. Finding, moderate evidencelowersMean arterial pressure
  3. Finding, moderate evidencelowersSystolic blood pressure
Study, every finding
RCT · 6 months
Dose studied, every finding
1500 mg/day dry extract (500 mg capsule three times daily)
Population, every finding
adults with moderate-to-severe generalized anxiety disorder who responded to 12 weeks of open-label chamomile extract, then randomized to continue chamomile or switch to placebo for 26 weeks
  • “During the 26-week continuation phase, the chamomile group had a relatively lower weight than the placebo group (P = 0.046; Fig. 4).”
  • “The chamomile group also had significantly lower mean arterial blood pressure (P = 0.0063; Fig. 5) and systolic pressure (P = 0.0012), and had a non-significant trend toward lower diastolic pressure (P = 0.057).”

Study record

Design
randomised controlled trial
Species
human
Population
Outpatients with moderate-to-severe generalized anxiety disorder who responded to 12 weeks of open-label chamomile extract, randomized to continuation chamomile or placebo
Participants
93
Comparator
placebo
Duration
182 days
Endpoints measured
17